Literature DB >> 18186892

Complications of chronic kidney disease in children post-renal transplantation - a single center experience.

Janusz Feber1, Hubert Wong, Pavel Geier, Bushra Chaudry, Guido Filler.   

Abstract

Similar to adults, CKD may persist after pediatric RTx. Clinical and laboratory parameters were analyzed retrospectively in 23 RTx recipients (13 males, age 11.9 +/- 5.2 yr), initially treated with prednisone, calcineurin inhibitor (TAC = 18, cyclosporine neoral = 5), and MMF at four months post-RTx (T1) and at 3.4 +/- 2.8 yr post-RTx (T2). Mean (+/-s.d.) cystatin C GFR (mL/min/1.73 m(2)) was 72 +/- 19 at T1 and 70 +/- 22 at T2 (NS). At T2, CKD stage I was present in five patients (22%), stage II in eight patients (35%), and stage III in 10 patients (43%). At T2, calcineurin inhibitors were utilized in 19, MMF in 13, and SIR in 13 patients. The prevalence of hypertension was 69% at T1 and 87% at T2 (p = NS). Anemia was diagnosed in 61% at T1 and 69% at T2 with average therapeutic MMF (2.78 +/- 1.3 mg/mL) and SIR (7.62 +/- 2.3 mg/mL) trough levels. Hypercholesterolemia was detected in 44.0% at T1 and 47% at T2. Bone disease was diagnosed in 26.0% at T1 and 21.7% at T2. Mean height Z-scores were -1.0 +/- 1.2 (T1) and -1.0 +/- 1.59 (T2, NS), with 21% at T1 and 30% at T2 below two SDS. We observed suboptimal growth, hypertension, hypercholesterolemia, bone disease, and anemia in a significant proportion of transplanted children.

Entities:  

Mesh:

Year:  2008        PMID: 18186892     DOI: 10.1111/j.1399-3046.2007.00782.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  9 in total

1.  Proteinuria 1 year after renal transplantation is associated with impaired graft survival in children.

Authors:  Tomáš Rosík; Mária Chadimová; Jiří Dušek; Jaromír Háček; Naděžda Šimánková; Karel Vondrák; Jakub Zieg; Tomáš Seeman
Journal:  Pediatr Nephrol       Date:  2015-04-30       Impact factor: 3.714

2.  Bone assessment in children with chronic kidney disease: data from two new bone imaging techniques in a single-center pilot study.

Authors:  Justine Bacchetta; Stéphanie Boutroy; Nicolas Vilayphiou; Bruno Ranchin; Anne Fouque-Aubert; Odile Basmaison; Pierre Cochat
Journal:  Pediatr Nephrol       Date:  2011-01-20       Impact factor: 3.714

Review 3.  Anemia in Pediatric Kidney Transplant Recipients-Etiologies and Management.

Authors:  Anne Kouri; Shanthi Balani; Sarah Kizilbash
Journal:  Front Pediatr       Date:  2022-06-20       Impact factor: 3.569

4.  Anemia in children following renal transplantation-results from the ESPN/ERA-EDTA Registry.

Authors:  Leah A Krischock; Karlijn J van Stralen; Enrico Verrina; E Jane Tizard; Marjolein Bonthuis; György Reusz; Farida K Hussain; Augustina Jankauskiene; Gregor Novljan; Brankica Spasojević-Dimitrijeva; Ludmila Podracka; Vera Zaller; Kitty J Jager; Franz Schaefer
Journal:  Pediatr Nephrol       Date:  2015-09-18       Impact factor: 3.714

Review 5.  Cardiovascular disease in CKD in children: update on risk factors, risk assessment, and management.

Authors:  Amy C Wilson; Mark M Mitsnefes
Journal:  Am J Kidney Dis       Date:  2009-08       Impact factor: 8.860

6.  Developmental changes of MPA exposure in children.

Authors:  Elisa C Yoo; Ana Catalina Alvarez-Elías; Ekaterina Kirilova Todorova; Guido Filler
Journal:  Pediatr Nephrol       Date:  2016-01-07       Impact factor: 3.714

Review 7.  Treatment strategies to minimize or prevent chronic allograft dysfunction in pediatric renal transplant recipients: an overview.

Authors:  Britta Höcker; Burkhard Tönshoff
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

8.  No association between cyclosporine levels and dyslipidemia?

Authors:  Guido Filler
Journal:  Nephrourol Mon       Date:  2014-01-13

9.  Does Vitamin D Affect Chronic Renal Allograft Function in Pediatric Transplant Patients?

Authors:  Brooke Wile; Elisa Yoo; Ana Catalina Alvarez Elias; Lakshmimathy Subramanian; Kathryn Eager; Ajay Parkesh Sharma; Guido Filler
Journal:  Ann Transplant       Date:  2018-04-17       Impact factor: 1.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.